SIC 2836 – Biological Products, Except Diagnostic Substances (Biotech)
| Valuation | |
|---|---|
| Market Cap ($M) | 52.51 |
| Enterprise Value ($M) | -11.06 |
| Book Value ($M) | 56.39 |
| Book Value / Share | 5.38 |
| Price / Book | 0.93 |
| NCAV ($M) | 14.99 |
| NCAV / Share | 1.43 |
| Price / NCAV | 3.50 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | 0.08 |
| Return on Assets (ROA) | 0.04 |
| Return on Equity (ROE) | 0.19 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 6.34 |
| Current Ratio | 6.34 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 94.99 |
| Assets | 136.39 |
| Liabilities | 80.00 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 68.70 |
| Operating Income | -26.16 |
| Net Income | 7.17 |
| Earnings Per Share Basic And Diluted | n/a |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | -58.45 |
| Cash from Investing | -0.21 |
| Cash from Financing | 50.45 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G | Readout Capital, LP | 8.90 | ||
| 13G | Weinstein Benjamin | 5.20 | ||
| 13G | Lynx1 Capital Management LP | 9.99 | ||
| 13G/A | Aquilo Capital Management, LLC | 9.90 | 19.50 | |
| 13G/A | Janus Henderson Group Plc | 0.00 | -100.00 | |
| 13G/A | Novartis Pharma Ag | 5.40 | -96.67 | |
| 13G | Highbridge Capital Management Llc | 5.30 | ||
| 13G/A | Tang Capital Management Llc | 8.60 | ||
| 13G/A | Perceptive Advisors Llc | 5.90 | -14.74 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| File Date | Form | SEC Filings |
|---|---|---|
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q | ||
(click for more detail) |
||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 22,298 | 96,956 | 23.00 | |
| 38,988 | 142,741 | 27.31 | |
| 315,872 | 906,550 | 34.84 | |
| 10,914 | 53,300 | 20.48 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| DRMA – Dermata Therapeutics, Inc. | DRRX – DURECT Corporation |
| DRUG – Bright Minds Biosciences Inc. | DWTX – Dogwood Therapeutics, Inc. |
| DYAI – Dyadic International, Inc. |
Financial data and stock pages provided by
Fintel.io